Armata Pharmaceuticals Inc. (ARMP), a biotechnology company focused on pathogen-specific bacteriophage therapeutics, on Thursday announced positive topline results from its Phase 2 Tailwind study.
Tailwind is a phase II clinical study evaluating inhaled AP-PA02 for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients.
The study included two cohorts: one receiving inhaled AP-PA02 as monotherapy, and the other receiving AP-PA02 in combination with inhaled antibiotics.
The primary efficacy endpoint was the reduction in Pseudomonas aeruginosa colony forming units ("CFUs") in the lung sputum at one week following completion of dosing (day 17) compared to baseline.
According to the trial findings, there was a statistically significant reduction in Pseudomonas aeruginosa colony-forming units (CFUs) in the lung at days 17 and 24, with AP-PA02 alone showing comparable efficacy to combination therapy.
This provides encouraging evidence of AP-PA02's potential as an effective treatment for chronic pulmonary infections caused by drug-resistant bacteria.
The safety data showed that AP-PA02 was well-tolerated, with treatment-emergent adverse events being mild and self-limiting. One serious adverse event related to an acute pulmonary issue required hospitalization, but it was successfully treated with antibiotics.
Overall, the safety and tolerability profile of AP-PA02 was positive.
Dr. Deborah Birx, CEO of Armata Pharmaceuticals, commented, "The promising results from the Tailwind study highlight the potential of our phage-based therapy as a new treatment option for chronic pulmonary infections caused by drug-resistant P. aeruginosa. We remain focused on advancing AP-PA02 as a potential therapeutic for patients with NCFB."
ARMP closed Wednesday's (Dec.18.2024) trading at $1.95, down 2.50%. In premarket trading, the stock is up by 4.10% at $2.03.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.